Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the safety and efficacy of Mosunetuzumab in combination with Polatuzumab Vedotin in B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Polivy (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING